08:53 AM EDT, 10/31/2024 (MT Newswires) -- Insmed ( INSM ) reported a Q3 net loss Thursday of $1.27 per diluted share, wider than the loss of $1.11 a year earlier.

Analysts polled by Capital IQ expected a loss of $1.21.

Net product revenues for the quarter ended Sept. 30 were $93.4 million, up from $79.1 million a year earlier.

Analysts surveyed by Capital IQ expected $93.2 million.

The company said it continues to expect fiscal 2024 revenue for antibiotic drug Arikayce to be between $340 million and $360 million.

Shares of the company were down 7.3% in recent premarket activity.

Price: 65.16, Change: -5.13, Percent Change: -7.30